Dr. Demetri’s research and clinical interests have focused on the development of targeted therapies for sarcomas and other solid tumors. The contributions of Dr. Demetri and his colleagues at Dana-Farber/Harvard Cancer Center have led to the development of cancer treatments such as Gleevec and Sutent. Dr. Demetri received an undergraduate degree from Harvard University and a medical degree from Stanford University School of Medicine. After completing Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle, Washington, he pursued a fellowship in Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an attending physician since 1989. Dr. Demetri serves as co-chair of the Medical Advisory Board for the Sarcoma Alliance for Research through Collaboration (SARC) and Executive Director for Clinical and Translational Research in the Ludwig Center for Cancer Research, the largest philanthropic organization supporting cancer research.